Dr Belch has also been an active supporter of Myeloma Canada and the Myeloma Canada Research Network since its inception almost 15 years ago, including having once served as Chair of the Myeloma Canada Scientific Advisory Board. He and frequent research collaborators, Dr Linda Pilarski, have worked together to help “Canadianize” treatments and trials to ensure the care our community receives continues to be the best that’s available. Dr Belch kick-started the MCRN 003 (KCd) trial along with Dr Chris Venner. As of January 31, 2018, the trial was fully accrued with participation from 9 Canadian sites.
The Canadian myeloma community has benefited tremendously from his wisdom and expertise and we are extremely grateful for all of his contributions to having accelerated the quality of treatment and care we receive. We also appreciate his mentorship of the many clinicians and researchers who have benefited from his knowledge and tenacity. On behalf of all of us impacted in any way by myeloma, thank you!